It is tempting to speculate that therapeutic inhibition of FasL may also provide benefit to patients developing severe disease as a consequence of infection by other respiratory RNA viruses, including those with pandemic-causing potential that may emerge in the human population in the future [55]. This evidence concerns the gene FASLG and infection.